Kestra Private Wealth Services LLC Has $946,000 Holdings in Sanofi (NASDAQ:SNY)

Kestra Private Wealth Services LLC lowered its position in shares of Sanofi (NASDAQ:SNY) by 23.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,604 shares of the company’s stock after selling 5,971 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Sanofi were worth $946,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its stake in Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares during the period. Arkadios Wealth Advisors increased its stake in Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after buying an additional 751 shares during the period. Geode Capital Management LLC increased its stake in Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after buying an additional 16,780 shares during the period. JPMorgan Chase & Co. increased its stake in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares during the period. Finally, GFS Advisors LLC increased its stake in Sanofi by 1,017.9% in the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after buying an additional 11,655 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY opened at $53.99 on Friday. The company’s fifty day moving average is $50.18 and its 200-day moving average is $52.42. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The firm has a market cap of $137.02 billion, a price-to-earnings ratio of 21.68, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Equities analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several research reports. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.